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1. Introduction 
We have shown [ 11 that pyrazole administration 
to rats inhibits the hepatic activity of tryptophan 
oxygenase (EC 1.13.11 .ll). The lack of inhibitory 
effect on tryptophan oxygenase shown by pyrazole 
when added to liver homogenates together with the 
delayed nature of its effect in vivo suggests that the 
inactivator of tryptophan oxygenase is an active 
pyrazole derivative, as suggested [2] during studies 
concerned with pyrazole action on catalase 
(EC 1 .I 1.1.6), another hemoprotein enzyme. 
It has been shown [3,4] that the major metabolite 
of pyrazole in rats is 4-hydroxypyrazole and that 
4-hydroxypyrazole is a potent inhibitor of catalase 
in vitro. 
It seemed therefore of interest to test whether 
4-hydroxypyrazole affects tryptophan oxygenase 
activity, 
The present results show that 4.hydroxypyrazole 
inhibits tryptophan oxygenase activity in vitro, the 
inhibition being competitive with respect to trypto- 
phan. 
2. Materials and methods 
Female Wistar rats (150 ? 5 g) maintained on a 
standard laboratory diet and fasted during the over- 
night period immediately preceding the experiments, 
were used. 
4-Hydroxypyrazole was from Eli Lilly Co. 
(IndianapoIis). Hemin (crystalline, of bovine origin), 
~lsevier~.~orth-Holland Biomedical Press 
cortisol-2 1 -acetate and L-tryptophan were from 
Sigma (St Louis). 
The action of 4-hydroxypyrazole on tryptophan 
oxygenase activities was studied in liver homogenates 
prepared from cortisol-treated rats. Such rats were 
chosen in order to obtain liver homogenates having 
an elevated tryptophan oxygenase level. Cortisol-21- 
acetate (10 mglrat) was injected intraperitoneally and 
the animals sacrificed by decapitation 4 h after treat- 
ment. The whole liver was imlnediately exposed and 
frozen exactly 1 min after decapitation. T~ptophan 
oxygenase activity was determined by the method in 
[5] with the following minor modifications. The livers 
were homogenized in 9 vol. 0.15 M KC1 containing 
L-tryptophan (3 X lOA M)and NaOH(2.5 X 10m3 M). 
The homogenates were centrifuged (9000 X g) at 4°C 
for 20 min. 4-Hydroxypyrazole was dissolved in the 
sodium phosphate buffer and added at the start of 
the incubation. Preliminary experiments having 
shown that ascorbate interferes during kynurenine 
determination in the presence of 4-hydroxypyrazole, 
ascorbate was omitted during this incubation. The 
enzyme activity was expressed as micromoles of 
kynurenine formed per hour and per gram wet 
weight. 
3. Results 
Figure 1 shows the effects of varying the 
4-hydroxypyrazole concentration on tryptophan 
oxygenase activities. It appears that, at x0.1 mM, 
4-hydroxypyr~ole activates the enzyme, while a 
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Fig.1. Effects of varying the concentration of 4-hydroxy- 
pyrazole added in vitro to tryptophan oxygenase activities in 
rat liver homogenates. Tryptophan oxygenase activity was 
determined, asin section 2, either in the absence (holoenzyme 
activity) or in the presence (total enzyme activity) of added 
hematin (5 PM). The enzyme activity is expressed as prnol 
kynurenine formed h/g liver wet wt. Each point represents 
the mean value for 8 animals. 
dose-dependent sigmoidal decrease in the activities of 
the enzyme is observed at higher 4hydroxypyrazole 
concentrations. Such effects are observed on holo- 
enzyme as well as total enzyme activities. The inhibi- 
tion of total enzyme cannot be reversed by increasing 
the added hematin concentration (results not shown). 
The tryptophan oxygenase assay, which measures 
the appearance of kynurenine (and not formyl- 
kynurenine), depends on the presence of an excess of 
kynurenine formamidase. With formylkynurenine con- 
centration being measured at Aa2r it was found that 
the As6s/As2r remained constant at all 4-hydroxy- 
pyrazole concentrations tested. It appears thus that 
4-hydroxypyrazole does not lead to a relative accu- 
mulation of formylkynurenine. 
A Lineweaver-Burk plot shows that 4-hydroxy- 
pyrazole acts as a competitive inhibitor with respect 
to tryptophan (fig.2) the Ki being 3 X 10M5 M and 
the Km (tryptophan) 5 X lo4 M. 
Additional studies were designed to investigate the 
possible interaction of two or more sites on trypto- 
phan oxygenase when varying tryptophan and 
4-hydroxypyrazole concentrations. The arithmetical 
plot of velocity versus tryptophan concentration is 
shown fIg.3. The log of the fractional activation of 
tryptophan oxygenase (log v/V-v), when plotted 
against the log of tryptophan concentration, gives a 
maximum estimate for ‘PZ’ in the Hill equation of 1.47 
(fig.3); this result is in good agreement with that in 
Fig.2. Lineweaver-Burk plot of inhibition of tryptophan 
oxygenase by 4-hydroxypyrazole, with tryptophan as the 
variable substrate. Enzyme activity was determined in 
absence of added hematin (holoenzyme activity). Each point 
represents the mean value for 4 animals. The curves are as 
follows: (-o-o-) without 4-hydroxypyrazole; (-•--*-) 
with 0.10 mM 4-hydroxypyrazole; (-0-0~) with 0.15 mM 
4-hydroxypyrazole. The inset plots the app. Km against he 
concentration of 4-hydroxypyrazole. The intercept on the 
X-axis gives an estimate of Ki. 
[6]. Similar studies were done with 4-hydroxypyrazole 
at 0.025-0.25 mM, two concentrations of trypto- 
phan (1 mM and 3 mM) being used. Log-log plots 
of fractional velocity versus 4-hydroxypyrazole con- 
centration are presented in fig.4. They show that a 
Fig.3. Tryptophan oxygenase activity as a function of the 
concentration of L-tryptophan. The enzyme activity was 
determined in absence of added hematin. Log-log plot 
of fractional velocity versus L-tryptophan concentration 
are presented in the inset. Each point represents the mean 
value for 4 animals. Linear regression was used to fit the 
line through the data points. 
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Fig.4. Hill plot of activatory and inhibitory effects of 
4-hydroxypyrazole on liver tryptophan oxygenase. Only 
holoenzyme activity is determined. (-e--o-_) Curve is with 
1 mM tryptophan and varying concentration of 4-hydroxy- 
pyrazole; (-o-e-) curve is with 3 mM tryptophan. Linear 
regression was used to fit the line through the data points. 
negative slope with n = 1.77 is found at 1 mM 
L-tryptophan, whereas, at 3 mM L-tryptophan, an 
initial positive slope (n = 0.43) is followed by a 
negative slope (with y1 = 2.62) when the concentra. 
tion of 4-hydroxypyrazole is increased. 
4. Discussion 
The results obtained show that 4-hydroxypyrazole 
is in vitro a potent inhibitor of tryptophan oxygenase, 
1 mM determining a 90% inhibition of the enzyme 
activities. The fact that the Ki value is several times 
lower than the K,, value for tryptophan is indicative 
of its potency. This inhibitory activity seems, however, 
independent of the hematin concentration. 
The data for 4-hydroxypyrazole suggests that the 
drug interferes competitively with the binding of 
tryptophan. Since the Hill coefficient of 4-hydroxy- 
pyrazole increases with tryptophan concentrations 
(figA), tryptophan exhibits heterotropic interactions 
on the binding of 4-hydroxypyrazole. The mechanism 
of the activation of the enzyme which has been 
observed only when using a saturating tryptophan 
concentration and 4-hydroxypyrazole at <O.l mM is 
unclear. 
Our data suggest furthermore that the inhibition 
of tryptophan oxygenase found after pyrazole 
administration to rats [l] may be mediated through 
the formation of 4-hydroxypyrazole, which appears 
to have a much stronger inhibitory effect on trypto- 
phan oxygenase activities than pyrazole itself. As a 
matter of fact, we found [l] that doses of pyrazole 
at <l mM were without effect on tryptophan 
oxygenase in vitro, an inhibition of only 30% being 
observed when pyrazole is raised to 10 mM. Apparent- 
ly the hydroxysubstitution on the ring determines 
this potent inhibitory behaviour. Epinephrine and 
other phenols are also potent inhibitors of trypto- 
phan oxygenase in vitro and the contribution of the 
hydroxyl group has been pointed out [7]. 
The effects of pyrazole and 4-hydroxypyrazole 
on tryptophan oxygenase are closely similar to those 
described for catalase [2,4], another hemoprotein and 
for dopamine P-hydroxylase (EC 1.14.2.1) [B-lo], 
a copper protein. It appeared that the presence of a 
hydroxyl group on the pyrazole ring determines an 
inhibition of these metal-containing enzymes. 
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